In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam

Mengyun Yin,Guoping Hu,Zhen Shen,Chengli Fang,Xuefei Zhang,Dan Li,Yohei Doi,Yu Zhang,Minggui Wang,Qinglan Guo
DOI: https://doi.org/10.1128/aac.00562-20
IF: 5.938
2020-10-20
Antimicrobial Agents and Chemotherapy
Abstract:Here, we report a novel narrow-spectrum β-lactamase CTX-M-215 identified in an Escherichia coli clinical isolate in China and conferring high-level resistance to mecillinam but not to cefotaxime. CTX-M-215 differed from CTX-M-125, a CTX-M extended-spectrum β-lactamase (ESBL), by an N132D substitution, which decreased hydrolytic activities toward penicillins and cephalosporins except for mecillinam. High similarity was observed between CTX-M-215- and CTX-M-125-bearing plasmids, carried by different isolates in the same patient, indicating in vivo evolution of CTX-M-215 from CTX-M-125.
pharmacology & pharmacy,microbiology
What problem does this paper attempt to address?